Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.